Healthcare >> CEO Interviews >> August 25, 2003
BRUCE SELIGMANN, President, CEO and Chairman of High Throughput
Genomics, Inc., is responsible for the company's overall strategy and
business direction. Prior to High Throughput Genomics, he founded
combinatorial chemistry pioneer SIDDCO and served as its president, CEO
and chairman through its sale to Discovery Partners International and
the resulting divestiture of HTG. Prior to SIDDCO, Dr. Seligmann was
Center Director of Selectide. During his tenure with that company, he
tripled its size and staged it for purchase by Marion Merrill Dow (now
Aventis). Before Selectide, he was a senior research fellow at Ciba-
Geigy (now Novartis) for seven years. Dr. Seligmann also spent seven
years as a senior staff scientist at the National Institutes of Health,
National Institute of Allergy and Infectious Diseases and Laboratory of
Clinical Investigation, where he became internationally known for his
research. Dr. Seligmann earned his doctorate from the University of
Maryland and holds a BS in chemistry from Davidson College. Profile
Throughput Genomics and a picture of things as they are now?
Dr. Seligmann: High Throughput Genomics was originally a
